8th Apr 2022 16:01
Renalytix PLC - London-based diagnostics company focused on kidney health - Completes a USD8.8 million equity subscription and a USD21.2 million subscription for convertible bonds. Company raises USD26.8 million as a result. Proceeds will be used for general working capital purposes and to support company growth.
Chair Christopher Mills subscribed for a total of 551,724 shares at USD3.625 each. Mills now holds 13.0% of the company's share capital.
Directors Ann Berman and Timothy Scannell now hold 0.05% and 0.09% of the company's share capital, respectively, as a result of their subscriptions. President Thomas McLain holds 0.08% following his subscription.
Current stock price: 235.00 pence, down 2.1% in London
12-month change: down 75%
By Heather Rydings; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc